Sartorius (OTCMKTS:SARTF – Get Free Report) is expected to be issuing its resultson Thursday, July 23rd. Analysts expect the company to post earnings of $1.56 per share and revenue of $1.0658 billion for the quarter.
Sartorius Price Performance
OTCMKTS:SARTF opened at $212.80 on Thursday. Sartorius has a 52 week low of $181.58 and a 52 week high of $227.00. The stock’s fifty day moving average is $211.21 and its two-hundred day moving average is $220.42. The company has a market capitalization of $7.28 billion, a P/E ratio of 98.98 and a beta of 0.98. The company has a quick ratio of 0.49, a current ratio of 0.95 and a debt-to-equity ratio of 0.89.
Sartorius Company Profile
Sartorius AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.
The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies.
Recommended Stories
- Five stocks we like better than Sartorius
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.
